Effects of Omalizumab Treatment in Patients With Refractory Chronic Urticaria

Young-Hee Nam,1 Joo-Hee Kim,2 Hyun Jung Jin,1 Eui-Kyung Hwang,1 Yoo-Seob Shin,1 Young-Min Ye,1 Hae-Sim Park1*  

1Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea  
2Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose: Chronic urticaria (CU) is a common and debilitating disease, and the need for effective treatment has increased. Omalizumab may be an alternative regimen in patients with CU who do not respond to conventional treatments. The aim of this study is to investigate the efficacy and to observe the clinical results of omalizumab in patients with refractory CU.  

Methods: We conducted a retrospective analysis of 26 patients with refractory CU who were treated with omalizumab. Omalizumab was administered every 2 or 4 weeks, depending on body weight and the total serum IgE level, for 24 weeks.  

Results: Fourteen patients (53.8%) achieved remission after the treatment; they had a significantly higher prevalence of personal (P = 0.033) and family history of allergic diseases (P = 0.002) than those who did not achieve remission. During omalizumab treatment, the urticaria activity score declined significantly (12.11 ± 1.97 to 2.7 ± 4.23; P = 0.001) and the CU-quality of life score improved significantly (34.65 ± 13.58 to 60.88 ± 11.11; P = 0.004). There were significant decreases in the use of systemic steroids (42.3% ± 11.5%; P = 0.027) and immunomodulators (65.4% ± 19.2%; P = 0.002). The dose of antihistamines required to control CU also decreased significantly (215.66 ± 70.06 to 60.85 ± 70.53 mg/week of loratadine equivalents; P < 0.001). No serious adverse event was noted.  

Conclusions: These findings suggest that omalizumab can be an effective and safe treatment in patients with refractory CU.

Key Words: Chronic urticaria; refractory; omalizumab

INTRODUCTION

Chronic urticaria (CU) is a skin disorder characterized by the recurrent appearance of wheals and/or angioedema for more than 6 weeks.1,2 CU accounts for 25% of urticaria, and the prevalence of CU is 0.1%-0.6%.3,4 Almost 40% of CU patients continue to experience urticarial wheals 10 years later.5 CU has detrimental effects on the quality of life (QOL) and is associated with poorer general health and reduced emotional well-being.5-8 As a result, CU has a large impact on society in terms of healthcare costs.9,10 Patients with refractory CU do not respond to standard treatments with antihistamines or additional immunomodulators that are, in a few cases, unsafe when used for prolonged times.  

CU is a heterogeneous disorder and includes idiopathic, autoimmune, and physical urticaria and vasculitis.11 For more than 50% of patients with CU, the underlying cause has not been identified.12 However, up to one-third of patients with chronic idiopathic urticaria have autoantibodies to FcεRI (a high-affinity receptor for IgE), and about 10% have IgE autoantibodies.13 These autoantibodies can cause mast cell degranulation, and most CU symptoms result from the degranulation of skin mast cells. Omalizumab, a recombinant humanized monoclonal antibody, forms a biologically inert molecule with free IgE.14 Omalizumab selectively binds to the C3 domain of the IgE heavy chain, where IgE binds to FcεRI, and inhibits the reactions between anti-IgE and IgE-sensitized mast cells; thus, it can improve CU symptoms. Omalizumab was shown to be dramatically effec-
tive in chronic autoimmune urticaria, chronic idiopathic urticaria and various urticaria subtypes such as cholinergic, cold, solar, and non-autoimmune urticarial, as well as CU with IgE autoantibodies against thyroperoxidase. In the present study, we evaluated the efficacy and safety of omalizumab, and observed the clinical course of omalizumab treatment in 26 patients with refractory CU.

MATERIALS AND METHODS

We conducted a retrospective study of patients who were treated with omalizumab for refractory CU. Patients with refractory CU were defined as having symptoms for at least 6 weeks with persistent hives, and not controlled most days of the week, despite the use of a fourth-line therapy for more than 4 weeks, according to EAACI/GALEN guidelines. Omalizumab was administered subcutaneously every 2 or 4 weeks for 24 weeks, dosed according to the patient’s body weight and total serum IgE levels as described in previous studies. Atopy was defined as a positive skin prick test with at least one common aeroallergen or the presence of serum-specific IgE against at least one. Urticaria activity score (UAS) and chronic urticaria-specific QOL (CU-QOL) questionnaires were completed every 4 weeks. The UAS (total score range, 0-15, with higher scores indicating higher disease activity) was measured using a combination of pruritus and four characteristics of wheals, including number, distribution range, mean diameter, and duration. The patient’s health-related QOL was evaluated using a previously validated scoring system, the CU-QOL, comprising 17 items (total score range, 0-68, with higher scores indicating higher QOL). Medications were prescribed and stepped down with monitoring every 4 weeks following the EAACI/GALEN guidelines. In patients who achieved remission, the medications were stepped down. Drug requirements for antihistamines and steroids were calculated as described previously. Daily doses of H1-antihistamine drugs for the treatment of CU were calculated based on the equivalent dose of loratadine (10 mg/day), and the required antihistamine doses were calculated from the total antihistamine doses used for the control of CU during 4 weeks, presented as the equivalent dose (mg/week) of loratadine for the H1 antihistamine. Immunomodulators used included leukotriene receptor antagonists, cyclosporine, hydroxychloroquine, and colchicine.

The responses to omalizumab were described as follows: remission, defined as a condition with no symptoms and no requirement for medications for at least 4 weeks; responsive, defined as a step-down of more than one level of therapy compared with the baseline; and refractory, defined as neither remission nor any symptom improvement during the treatment period. The protocol for the study was approved by the Institutional Review Board of the hospital (AJIRB-MED-OBS-11-300).

RESULTS

Patient characteristics

Twenty-six patients were enrolled in the present study. The mean age was 43.1 ± 8.4 years, and 14 patients (53.8%) were men. The mean disease duration of CU was 63 ± 72.7 months. Seventeen subjects (68%) had atopy, 16 (61.5%) had nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity, and half of the subjects had angioedema or physical urticaria. Anti-nuclear antibody was detected in five patients (19.2%); antihygro-globulin antibody, in six patients (23.1%); and antimicrosomal antibody, in one patient (7.7%). The mean total IgE level was 247.7 ± 274.6 kU/mL.

Changes in the UAS, CU-QOL, and medication requirements

The UAS [12.11 ± 1.97 to 3.0 ± 4.28 at week 12 (P = 0.001) and to 2.7 ± 4.23 at week 24 (P = 0.001)] decreased significantly, while the CU-QOL score [34.65 ± 13.58 to 62.59 ± 8.71 at week 12 (P = 0.001) and to 60.88 ± 11.11 at week 24 (P = 0.004)] improved significantly during omalizumab treatment (Fig. 1). Eight of 11 subjects (72.7%, P = 0.027) discontinued systemic steroid use, and 12 of 17 (70.6%, P = 0.002) discontinued the use of any immunomodulator. The requirements for H1-antihistamines decreased significantly (215.66 ± 72.7 months).

![Fig. 1. Changes in urticaria activity score and chronic urticaria-specific quality of life score during IgE antibody (omalizumab) treatment.](http://e-aair.org/)
Treatment outcomes

Twenty-two patients (84.6%) achieved remission during 24 weeks (remitted group). Ten patients achieved remission at week 4; four, at week 12; three, at weeks 8 and 16; and one, at weeks 20 and 24 (total mean, 9.27 ± 6.1 weeks). In the remitted group, 14 (53.8%) maintained remission throughout the 24-week treatment period. However, symptoms recurred in eight (30.8%) of these subjects; the mean period for recurrence was 11 weeks (range, 4-20 weeks). Five (19.2%) maintained their baseline therapy, and the other three (11.6%) achieved step-down therapy. The causes of recurrence were alcohol (two cases), drugs (one case), coldness (two cases), and unknown causes (three cases). No significant differences were observed in clinical parameters, including age, gender, disease duration, atopy, angioedema, physical urticaria, and baseline UAS or CU-QOL score, or in medication schedules between the recurrent and remission maintenance groups. In the non-remitted group (n=4, 15.4%), two (7.7%) achieved step-down therapy and two (7.7%) were still refractory to omalizumab. One refractory patient had atopy and a history of NSAID hypersensitivity, and the other had atopic dermatitis. In total, 19 patients (73.1%) were responsive to omalizumab (Fig. 3).

No severe adverse events were observed during the treatment period. Only mild and tolerable adverse events were noted: facial rash (one case), dyspepsia (one case), weight loss (one case), and generalized edema (one case). All patients successfully fin-

Comparison of clinical parameters according to the response to omalizumab

The patients were divided into two groups according to whether they achieved remission at week 24:14 subjects with remission (group I) and 12 subjects without remission (group II; Table). No significant difference in age, gender, disease duration, atopy, angioedema, physical urticaria, or baseline UAS or CU-QOL score was observed between the groups. However, group I had a significantly higher prevalence of personal or family history of allergic diseases compared with group II (P=0.033 and P=0.002, respectively). NSAID hypersensitivity was higher in group II, although the difference was not significant (P=0.051). When comparing the responsive group with the unresponsive group, no significant difference was detected, except that the baseline CU-QOL score was lower in the responsive group (29.69 ± 11.11 vs. 50.75 ± 6.13, P=0.002; data not shown).

DISCUSSION

CU, one of the most frequent skin allergy diseases, is a heterogeneous condition, and prognostic factors for each treatment are not well known. Symptomatic treatment for CU is the most frequently used form of management, and a step-wise approach is recommended. First-line therapy with an antihistamine-based regimen may not achieve satisfactory control in 5% to as many as 50% of patients with CU. Those with refractory CU require the addition of cyclosporine, dapsone, or omalizumab to H1-antihistamines, and frequent exacerbations are treated

**Table.** Comparison of clinical parameters according to remission at week 24

| Parameter | Group I* (n=14) | Group II (n=12) | P value |
|-----------|----------------|----------------|---------|
| Age (yr)  | 43.86 ± 7.33  | 42.17 ± 9.71   | 0.595   |
| Males (%) | 7 (50)         | 7 (58.3)       | 0.713   |
| Duration of disease (months) | 78.93 ± 91.84 | 44.42 ± 36.82 | 0.494 |
| History of underlying disease | 4 (28.6) | 3 (25) | >0.9 |
| History of allergic disease | 14 (100) | 8 (66.7) | 0.033 |
| Angioedema | 6 (42.9) | 7 (58.3) | 0.695 |
| Physical urticaria | 8 (57.1) | 5 (41.7) | 0.695 |
| Atopy | 9 (69.2) | 8 (66.7) | >0.9 |
| NSAID hypersensitivity | 6 (42.9) | 10 (83.3) | 0.051 |
| Family history of allergic disease | 8 (57.1) | 0 | 0.002 |
| Baseline UAS* | 12.78 ± 1.72 | 11.44 ± 2.07 | 0.161 |
| Baseline CU-QOL score* | 29.11 ± 11.84 | 40.88 ± 13.32 | 0.074 |
| Log serum total IgE* (kU/mL) | 2.26 ± 0.49 | 2.08 ± 0.41 | 0.322 |

NSAID, nonsteroidal anti-inflammatory drug; UAS, urticaria activity score; CU-QOL, chronic urticaria-specific quality of life.

*Data are presented as mean ± standard deviation.

Subjects who achieved remission at week 24.

Subjects who could not achieve remission at week 24.
with systemic steroids. However, the toxicities and adverse events associated with cyclosporine and long-term steroid exposure should be considered carefully.\textsuperscript{15,20} Thus, a continuing need exists for effective and safe treatments for refractory CU; trials of several novel therapeutics are in progress.

Recent studies have demonstrated favorable effects of omalizumab in patients with refractory CU. Omalizumab significantly improved the UAS, health-related QOL, and medication use, with a rapid onset of effects that persisted for the duration of treatment.\textsuperscript{15,16,20,27} The onset of effects occurred after 1-2 weeks,\textsuperscript{15} and greater than 50% improvement in health-related QOL was noted.\textsuperscript{15,20} In the present study, when we analyzed 26 patients with refractory CU, the effects, including improvement in the UAS, CU-QOL score, and medication use, were comparable to previous findings.\textsuperscript{15-17,20} However, in eight patients, urticaria symptoms recurred during the treatment period, and medications had to be restarted to control the symptoms, which in half of these subjects recurred at week 24. These findings suggest that although long-term study results are needed, omalizumab may be considered as an alternative regimen for controlling refractory CU in patients who do not respond to conventional treatments.

A longer duration of disease, concurrent angioedema, the combination with physical urticaria, and a positive autologous serum skin test (ASST) are related to severe CU.\textsuperscript{15,29} While all patients with mild CU were symptom-free after 2 years, more than 30% of patients with moderate-to-severe symptoms appeared to continue to suffer at 5 years.\textsuperscript{29} At least 50% of patients with CU have angioedema,\textsuperscript{30} one-third show a positive response on the ASST,\textsuperscript{11,22} and the prevalence of CU in combination with physical urticaria is 10% to 50%.\textsuperscript{30,33,34} Generally, omalizumab could induce clinical remission in 50%-70% of Western patients with CU.\textsuperscript{15,20} However, no report has suggested any prognostic factors for predicting the response to omalizumab. In the present study, 53.8% of the patients achieved remission after omalizumab treatment, and half of them exhibited angioedema and physical urticaria. The presence of angioedema, physical urticaria, and the duration of disease were not related to treatment response. Instead, we found a significantly higher prevalence of personal or family history of allergic diseases in the remitted group than in the non-remitted group, indicating that a personal or family history of allergic diseases may be a favorable factor for predicting remission after omalizumab treatment in refractory CU.

Neither severe adverse reactions nor death have been reported in previous studies. Kaplan et al.\textsuperscript{15} reported no adverse effects. In another study, the rate of adverse events was similar between the omalizumab and placebo groups; the most frequent adverse events were diarrhea, followed by nasopharyngitis, upper respiratory infection, and headache.\textsuperscript{20} In the present study, minimal adverse reactions were reported in four cases, and no patient discontinued omalizumab treatment.

In conclusion, omalizumab is an effective and safe treatment for patients with refractory CU. The findings suggest that a personal or family history of allergic diseases may be a favorable factor for predicting remission. Further studies will be needed to investigate potential factors for differentiating favorable and unfavorable responders.

**ACKNOWLEDGMENTS**

This study was supported by a grant from the DaeWoo Foundation (2011).

**REFERENCES**

1. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, Grattan CE, Kapp A, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, Schünemann H, Staubach P, Vena GA, Wedi B, Maurer M; Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. EAACI/GA(2)LEN/EDF/VAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64:1417-26.

2. Greaves MW. Chronic urticaria. N Engl J Med 1995;332:1767-72.

3. Hellgren L. The prevalence of urticaria in the total population. Acta Allergol 1972;27:236-40.

4. Gaig P, Oliuna M, Muñoz Lejarazu D, Caballero MT, Domínguez F, Echechípia S, García Abujeta JL, Gonzalo MA, Lleonart R, Martínz Córera C, Rodríguez A, Ferrer M. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004;14:214-20.

5. Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C, Braido F, Majani G, Canonica GW. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy 2003;58:821-3.

6. O’Donnell BE, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136:197-201.

7. Caine N, Harrison SC, Sharples LD, Wallwork J. Prospective study of quality of life before and after coronary artery bypass grafting. BMJ 1991;302:511-6.

8. Yosipovitch G, Ansari N, Goon A, Chan YH, Goh CL. Clinical characteristics of pruritus in chronic idiopathic urticaria. Br J Dermatol 2002;147:32-6.

9. Delong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol 2008;144:136:197-201.

10. Kapp A, Demarteu N. Cost effectiveness of levocetirizine in chronic idiopathic urticaria: a pooled analysis of two randomised controlled trials. Clin Drug Investig 2006;26:1-11.

11. Grattan CE, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol 2002;46:645-57; quiz 57-60.

12. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003;3:363-8.

13. Sabroe RA, Fiebig G, Jankovic IA, Greaves MW, Barr RM. Classification of anti-
FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 2002;110:492-9.

14. Vichyanond P. Omalizumab in allergic diseases, a recent review. Asian Pac J Allergy Immunol 2011;29:209-19.

15. Kaplan AP, Joseph K, Maykut RJ, Guba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122:569-73.

16. Saini S, Rosen KE, Hsieh HJ, Conner E, Kaplan A, Specter S, Maurer M. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567-73.e1.

17. Groffik A, Mitzel-Kaoukhov H, Magelr M, Maurer M, Staabach P. Omalizumab—an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011;66:303-5.

18. Ketel A, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008;63:247-9.

19. Zuberbier T, Asero R, Bindels-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, Grattan CE, Kapp A, Maurer M, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, Schüenemann H, Staabach P, Vena GA, Wedi B. Dermatology Section of the European Academy of Allergology and Clinical Immunology. Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427-43.

20. Maurer M, Altrichter S, Bieber T, Biedermann T, Brütting M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Rueff F, Schäkel K, Sengupta K, Siedler C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staabach P. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128:202-9.e5.

21. Ye YM, Park JW, Kim SH, Choi JH, Hur GY, Lee HY, Lee EH, Park HS. Clinical evaluation of the computerized Chronic Urticaria-Specific Quality of Life questionnaire in Korean patients with chronic urticaria. Clin Exp Dermatol. Forthcoming 2012.

22. Lee EH, Park JW, Kim C, Kim SH, Lee Y, Choi JH, Ye YM, Park HS. Development and psychometric evaluation of chronic urticaria-specific quality of life scale (CU-QOL) [abstract]. Korean J Asthma Allergy Clin Immunol 2010;30 Suppl 2:S384.

23. Pålkehe NS, Kim SH, Ye YM, Hur GY, Cho BY, Park HS. Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria. Pharmacogenomics 2009;10:375-83.

24. Zuberbier T, Bindels-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, Kapp A, Koziel MM, Maurer M, Merk HE; Schäfer T, Simon D, Vena GA, Wedi B; EAACI/GA2LEN/EDF. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006;61:321-31.

25. Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998;138:635-8.

26. Grattan CE, Humphreys F; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol 2007;157:1116-23.

27. Ferrer M, Gamboa P, Sanz ML, Goikoaetxe MA, Cabrera-Freitag P, Javaloyes G, Berroa F, Kaplan AP. Omalizumab is effective in non-autoimmune urticaria. J Allergy Clin Immunol 2011;127:1300-2.

28. Maurer M, Weller K, Bindels-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CE, Greaves MW, Hide M, Kalogeromitros D, Kaplan AP, Saini SS, Zhu XJ, Zuberbier T. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011;66:317-30.

29. Touchi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem D, Panasof J. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004;59:689-73.

30. Champion RH, Roberts SO, Carpenter RG, Roger JH. Urticaria and angio-oedema. A review of 554 patients. Br J Dermatol 1969;81:588-97.

31. Caproni M, Volpi W, Giomini C, Cardinale C, Antiga E, Melani L, Dagata A, Fabbri P. Chronic idiopathic and chronic autoimmune urticaria: clinical and immunopathological features of 68 subjects. Acta Derm Venereol 2004;84:288-90.

32. Metz M, Giménez-Arnau A, Borzova E, Grattan CE, Magelr M, Maurer M. Frequency and clinical implications of skin auto-reactivity to serum versus plasma in patients with chronic urticaria. J Allergy Clin Immunol 2009;123:705-6.

33. Tanaka T, Kameyoshi Y, Hide M. Analysis of the prevalence of subtypes of urticaria and angioedema. Arerugi 2006;55:134-9.

34. van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic spontaneous urticaria and correlation with disease severity. J Allergy Clin Immunol 2002;110:492-9.

35. Palikhe NS, Kim SH, Ye YM, Hur GY, Cho BY, Park HS. Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria. Pharmacogenomics 2009;10:375-83.

36. Zuberbier T, Bindels-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, Kapp A, Koziel MM, Maurer M, Merk HE; Schäfer T, Simon D, Vena GA, Wedi B; EAACI/GA2LEN/EDF. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006;61:321-31.

37. Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998;138:635-8.